Cubist Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of anti-infective products. The company primarily focuses on addressing gastrointestinal infections and related diseases that have limited treatment options. Its notable late-stage product candidates include fidaxomicin, an antibacterial drug designed for the treatment of Clostridium difficile-associated diarrhea, and Pruvel (prulifloxacin). In addition to these, Optimer's portfolio comprises CEM-101, OPT-822/OPT-821 combination therapy, and OPT-88. The company aims to create therapies that significantly improve patient outcomes and alleviate the burden of infectious diseases.

Trius Therapeutics is a biopharmaceutical company based in San Diego, California, dedicated to the discovery, development, and commercialization of innovative antibiotics aimed at treating life-threatening infections. The company has successfully completed two Phase 3 clinical trials for its lead product, Tedizolid Phosphate, a second-generation oxazolidinone designed for the treatment of serious gram-positive bacterial infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). As bacterial resistance to existing antibiotics continues to rise, the need for new therapeutics to combat multi-drug resistant infections becomes increasingly urgent. Trius Therapeutics is led by a skilled management team with extensive experience in drug development and regulation, contributing to the company's efforts to address critical healthcare challenges posed by antibiotic resistance.

Adolor Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of prescription pain and pain-management products. ENTEREG (alvimopan) is the United States Food and Drug Administration (FDA) approved product. ENTEREG is indicated to accelerate upper and lower gastrointestinal (GI) recovery following partial large or small bowel resection surgery with primary anastomosis. The Company is conducting two Phase 2 clinical trials of ADL5945 to treat opioid-induced constipation (OIC), a condition that often results from long-term use of opioid analgesics in the management of chronic pain conditions. In addition, it is continuing development efforts on ADL7445, a second peripherally-acting mu opioid receptor antagonist, which is considered a back-up compound in its OIC program. The Company has completed Phase 1 clinical evaluation of ADL6906 (beloxepin).

Calixa Therapeutics, Inc. is a privately-held biopharmaceutical company dedicated to developing novel antibiotics to combat multi-drug resistant organisms, particularly gram-negative bacteria. The company’s lead product, CXA-101, is an intravenous formulation of a unique cephalosporin that demonstrates significant potency against multi-drug resistant Pseudomonas aeruginosa, a bacterium recognized as a serious threat by the infectious diseases community. Calixa is also developing a combination product, CXA-201, which pairs CXA-101 with a β-lactamase inhibitor. This combination aims to establish a first-line therapeutic option for hospitalized patients with severe infections caused by gram-negative organisms, addressing a critical unmet medical need in the treatment of resistant infections.

FORMA Therapeutics is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, specializing in the development and commercialization of innovative therapeutics for rare hematologic diseases and various cancers. The company's notable product candidates include FT-4202, currently in Phase 1 trials for sickle cell disease and other hemoglobinopathies, and FT-7051, which targets metastatic castration-resistant prostate cancer. Additionally, FORMA is advancing FT-2102, an oral investigational agent designed to inhibit mutated IDH1 enzymes, now being evaluated in Phase 2 trials for relapsed/refractory acute myeloid leukemia and exploratory Phase 1 trials for glioma. The company also develops FT-4101 and FT-8225, selective inhibitors of fatty acid synthase. By integrating advanced drug discovery technologies and oncology expertise, FORMA aims to target challenging biological pathways that contribute to cancer, thereby enhancing the development of small molecule drug candidates with unique mechanisms of action.

Illumigen Biosciences is a drug discovery and development firm focused on creating treatments for hepatitis C virus infections. The company employs proprietary genetic technologies to identify human genetic mutations that can inform the mechanisms of therapeutic drugs. Through its innovative approach, Illumigen aims to advance the understanding and treatment of this viral infection, contributing to the broader field of virology and drug development.